North America Multiple Sclerosis Therapeutics Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Drug Class (Immunosuppressant and Immunomodulators), Route of Administration (Injectable and Oral), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E-Commerce)
Market Introduction
Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system. Multiple sclerosis is a widespread disabling neurological condition, mostly diagnosed in people in the age group 20–50 years. It is a potentially debilitating disease, causing disruption in communication and coordination functions of the body.
Get more information on this report :
Market Overview and Dynamics
The North America multiple sclerosis therapeutics market is expected to reach US$ 15,269.74 million by 2027 from US$ 9,144.98 million in 2019; it is estimated to grow at a CAGR of 6.8% from 2020 to 2027. The growth of the market is attributed to a few key driving factors such as the increasing prevalence of multiple sclerosis and rising funding for multiple sclerosis research. However, the high cost of the multiple sclerosis treatment hinders the market growth.
As per the National Multiple Sclerosis Society’s study in 2017, about 1 million adults (up to 913,925) were suffering from MS in the US. Therefore, the growing prevalence of multiple sclerosis is driving the growth of the North America multiple sclerosis therapeutics market. Due to rise in funding, extensive research is being carried on developing novel medicines and treatments for multiple sclerosis and other ways of identifying potential causes for multiple sclerosis. Various organizations such as National Institute of Neurological Disorders and Stroke, National MS Society, and Parkinson’s Action Network are undertaking extensive efforts to create novel therapies for MS, which is driving the growth of the market.
North America is recording the growing number of COVID-19 cases. Patients suffering from chronic health conditions, such as neurological diseases, are reporting delays in treatment. Several companies are cutting their clinical trial activities and delaying product launches in response to the COVID-19 pandemic. However, amid pandemic, many companies and research institutes in the US are taking an initiative to study the neurological manifestations of COVID-19. To accelerate research into the diagnosis, prevention, and treatment of the neurological complications due to COVID-19, several initiatives have been initiated. These factors are positively influencing the North America multiple sclerosis therapeutics market to a extent.
Key Market Segments
The North America multiple sclerosis therapeutics market, by drug class, is bifurcated into immunosuppressant and immunomodulators. The immunomodulators segment held a larger share of the market in 2019, whereas the immunosuppressants segment is anticipated to register a higher CAGR in the market during the forecast period.
By route of administration, the North America multiple sclerosis therapeutics market is bifurcated into injectable and oral. The injectable segment held a larger share of the market in 2019, and the same segment is anticipated to register a higher CAGR in the market during the forecast period.
Based on distribution channel, the North America multiple sclerosis therapeutics market is segmented into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacies segment held the largest share of the market in 2019, whereas the e-commerce segment is estimated to register the highest CAGR in the market during the forecast period.
Major Sources and Companies Listed
Some of the primary and secondary sources associated with this report on the North America multiple sclerosis therapeutics market are the Ministry of Health and Prevention (MoHAP), U.S Centers for Disease Control and Prevention (CDC), National MS Society and Multiple Sclerosis Association of America (MSAA).
Reasons to buy the report
- Determine prospective investment areas based on a detailed trend analysis of North America multiple sclerosis therapeutics market over the next years.
- Gain an in-depth understanding of the underlying factors driving demand for different addictions therapeutics segments in the top spending countries and identify the opportunities offered by each of them.
- Strengthen your knowledge of the market in terms of demand drivers, industry trends, and the latest technological developments, among others.
- Identify the major channels driving the North America multiple sclerosis therapeutics market, providing a clear picture of future opportunities that will help Analyze, resulting in revenue expansion.
- Channelize resources by focusing on the ongoing programs undertaken by the different countries within the North America multiple sclerosis therapeutics market.
NORTH AMERICA MULTIPLE SCLEROSIS THERAPEUTICS MARKET SEGMENTATION
By Drug Class
- Immunosuppressant
- Immunomodulators
By Route of Administration
- Injectable
- Oral
- Hospital Pharmacies
- Retail Pharmacies
- E-Commerce
By Country
- US
- Canada
- Mexico
Company Profiles
- Merck & Co., Inc.
- Novartis AG
- Bayer AG
- Sanofi
- Bristol-Myers Squibb Company
- Horizon Therapeutics plc
- TEVA PHARMACEUTICAL INDUSTRIES LTD
- Takeda Pharmaceutical Company Limited
- F. HOFFMANN-LA ROCHE LTD
- Biogen
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Multiple Sclerosis Therapeutics Market – By Drug Class
1.3.2 North America Multiple Sclerosis Therapeutics Market – By Route of Administration
1.3.3 North America Multiple Sclerosis Therapeutics Market – By Distribution Channel
1.3.4 North America Multiple Sclerosis Therapeutics Market – By Country
2. Multiple Sclerosis Therapeutics Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Multiple Sclerosis Therapeutics– Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America – PEST Analysis
4.3 Expert Opinions
5. Multiple Sclerosis Therapeutics Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Growing Prevalence of Multiple Sclerosis (MS)
5.1.2 Rising Funding for Multiple Sclerosis Research
5.2 Market Restraints
5.2.1 High Cost of Multiple Sclerosis Treatment
5.3 Market Opportunities
5.3.1 Increasing Awareness About Multiple Sclerosis
5.4 Future Trends
5.4.1 Development and Launch of Innovative Products
5.5 Impact analysis
6. Multiple Sclerosis Therapeutics Market – North America Analysis
6.1 North America Multiple Sclerosis Therapeutics Market Revenue Forecast and Analysis
7. Multiple Sclerosis Therapeutics Market Analysis – By Drug Class
7.1 Overview
7.2 Multiple Sclerosis Therapeutics Market Revenue Share, by Drug Class (2019 and 2027)
7.3 Immunosuppressant
7.3.1 Overview
7.3.2 Immunosuppressant: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
7.4 Immunomodulators
7.4.1 Overview
7.4.2 Immunomodulators: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8. Multiple Sclerosis Therapeutics Market Analysis – By Route of Administration
8.1 Overview
8.2 Multiple Sclerosis Therapeutics Market Revenue Share, by Route of Administration (2019 and 2027)
8.3 Injectable
8.3.1 Overview
8.3.2 Injectable: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.4 Oral
8.4.1 Overview
8.4.2 Oral: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
9. Multiple Sclerosis Therapeutics Market Analysis – By Distribution Channel
9.1 Overview
9.2 Multiple Sclerosis Therapeutics Market Share, by Distribution Channel, 2019 and 2027
9.3 Hospital Pharmacies
9.3.1 Overview
9.3.2 Hospital Pharmacies: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
9.4 Retail Pharmacies
9.4.1 Overview
9.4.2 Retail Pharmacies: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
9.5 E-Commerce
9.5.1 Overview
9.5.2 E-Commerce: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
10. Multiple Sclerosis Therapeutics Market Analysis and Forecast To 2027 – North America Analysis
10.1 North America: Multiple Sclerosis Therapeutics Market
10.1.1 Overview
10.1.2 North America: Multiple Sclerosis Therapeutics Market, by Country, 2019 & 2027 (%)
10.1.3 US: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.1.3.1 US: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.1.3.2 US: Multiple Sclerosis Therapeutics Market, by Drug Class, 2018–2027 (USD Million)
10.1.3.3 US: Multiple Sclerosis Therapeutics Market, by Route of Administration 2018–2027 (USD Million)
10.1.3.4 US: Multiple Sclerosis Therapeutics Market, by Distribution Channel 2018–2027 (USD Million)
10.1.4 Canada: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.1.4.1 Canada: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.1.4.2 Canada: Multiple Sclerosis Therapeutics Market, by Drug Class, 2018–2027 (USD Million)
10.1.4.3 Canada: Multiple Sclerosis Therapeutics Market, by Route of Administration 2018–2027 (USD Million)
10.1.4.4 Canada: Multiple Sclerosis Therapeutics Market, by Distribution Channel 2018–2027 (USD Million)
10.1.5 Mexico: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.1.5.1 Mexico: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.1.5.2 Mexico: Multiple Sclerosis Therapeutics Market, by Drug Class, 2018–2027 (USD Million)
10.1.5.3 Mexico: Multiple Sclerosis Therapeutics Market, by Route of Administration 2018–2027 (USD Million)
10.1.5.4 Mexico: Multiple Sclerosis Therapeutics Market, by Distribution Channel, 2018–2027 (USD Million)
11. Impact of COVID-19 Pandemic on North America Multiple Sclerosis Therapeutics Market
11.1 North America: Impact Assessment of COVID-19 Pandemic
12. Industry Landscape
12.1 Overview
12.2 Organic Developments
12.2.1 Overview
12.3 Inorganic Developments
12.3.1 Overview
13. Company Profiles
13.1 Merck & Co., Inc.
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Novartis AG
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Bayer AG
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Sanofi
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Bristol-Myers Squibb Company
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Horizon Therapeutics plc
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 TEVA PHARMACEUTICAL INDUSTRIES LTD
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Takeda Pharmaceutical Company Limited
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 F. HOFFMANN-LA ROCHE LTD.
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Biogen
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. US Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 2. US Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 3. US Multiple Sclerosis Therapeutics Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 4. Canada Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 5. Canada Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 6. Canada Multiple Sclerosis Therapeutics Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 7. Mexico Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 8. Mexico Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 9. Mexico Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 10. Organic Developments Done by Companies
Table 11. Inorganic Developments Done By Companies
Table 12. Glossary of Terms, Multiple sclerosis therapeutics Market
LIST OF FIGURES
Figure 1. Multiple Sclerosis Therapeutics Market Segmentation
Figure 2. Multiple Sclerosis Therapeutics Market Segmentation, By Country
Figure 3. Multiple Sclerosis Therapeutics Market Overview
Figure 4. Immunomodulators Segment by Drug Class Held the Larger Share
Figure 5. North America Multiple Sclerosis Therapeutics Market, by Country (US$ Million)
Figure 6. North America PEST Analysis
Figure 7. Multiple Sclerosis Therapeutics Market Impact Analysis of Driver and Restraints
Figure 8. North America Multiple Sclerosis Therapeutics Market – Revenue Forecast and Analysis – 2019- 2027
Figure 9. Multiple Sclerosis Therapeutics Market Revenue Share, by Drug Class (2019 and 2027)
Figure 10. Immunosuppressant: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
Figure 11. Immunomodulators: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
Figure 12. Multiple Sclerosis Therapeutics Market Revenue Share, by Route of Administration (2019 and 2027)
Figure 13. Injectable: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
Figure 14. Oral: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
Figure 15. Multiple Sclerosis Therapeutics Market Share, by Distribution Channel, 2019 and 2027
Figure 16. Hospital Pharmacies: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
Figure 17. Retail Pharmacies: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
Figure 18. E-Commerce: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
Figure 19. North America: Multiple Sclerosis Therapeutics Market, by Key Country – Revenue (2019) (USD Million)
Figure 20. North America: Multiple Sclerosis Therapeutics Market, by Country, 2019 & 2027 (%)
Figure 21. US: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 22. Canada: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 23. Mexico: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 24. Impact of COVID-19 Pandemic in North American Country Markets
- Merck & Co., Inc.
- Novartis AG
- Bayer AG
- Sanofi
- Bristol-Myers Squibb Company
- Horizon Therapeutics plc
- TEVA PHARMACEUTICAL INDUSTRIES LTD
- Takeda Pharmaceutical Company Limited
- F. HOFFMANN-LA ROCHE LTD
- Biogen
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America multiple sclerosis therapeutics market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the North America multiple sclerosis therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.